<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02761577</url>
  </required_header>
  <id_info>
    <org_study_id>16012011</org_study_id>
    <nct_id>NCT02761577</nct_id>
  </id_info>
  <brief_title>A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia</brief_title>
  <official_title>A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia With the Use of Standard Laboratory Measures and Novel Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinical Hospital Centre Zagreb</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinical Hospital Centre Zagreb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is analysis of the incidence of contrast-induced nephropathy (CIN) in patients with
      previously normal renal function undergoing angiography and comparison between the three
      different treatment protocols on renal function.

      Patients are randomly assigned to the three groups: 1) peroral hydration, 2) Na bicarbonate
      (NaHCO3), and 3) NaHCO3 plus N-acetylcysteine (NAC) infusion.

      Serum creatinine (SCr), blood urea nitrogen (BUN), and neutrophil gelatinase-associated
      lipocalin (NGAL) are measured before and 48 hours after the angiography. CIN was defined as
      an absolute increase of 0.5 mg/dL or a relative increase of &gt;25% in creatinine levels 48-72
      hours after the procedure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomly assigned to the three groups: 1) peroral hydration, 2) Na bicarbonate
      (NaHCO3), and 3) NaHCO3 plus N-acetylcysteine (NAC) infusion The first group of patients
      receives standard peroral hydration of 1500 ml water on the day of the procedure.

      The second group receives 3 mL/kg/hour of Na bicarbonate, an hour prior to angiography and 1
      mL/kg/hour, within six hours after angiography.

      The third group receives parenteral NAC (1200 mg twice a day) one day before angiography, on
      the day of the angiography, and one day after the diagnostic procedure in addition to Na
      bicarbonate solution on the day of the angiography.

      The low-osmolar iodinated contrast agent was used.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function before and after diagnostic procedure by measuring Serum creatinine in Âµmol/mL</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of serum creatinine before and after diagnostic procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood urea nitrogen in mmol/L</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of blood urea nitrogen before and after diagnostic procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil gelatinase-associated lipocalin in ng/mL</measure>
    <time_frame>48 hours</time_frame>
    <description>measure of neutrophil gelatinase-associated lipocalin before and after diagnostic procedure</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Contrast Media Reaction</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>perorally 1500 ml water on the day of the procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mL/kg/hour IV (in vein) of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>N-acetylcysteine plus Sodium bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure in addition to Sodium bicarbonate solution on the day of the angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium bicarbonate</intervention_name>
    <description>3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography</description>
    <arm_group_label>Sodium bicarbonate</arm_group_label>
    <arm_group_label>N-acetylcysteine plus Sodium bicarbonate</arm_group_label>
    <other_name>NaHCO3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetylcysteine</intervention_name>
    <description>N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure</description>
    <arm_group_label>N-acetylcysteine plus Sodium bicarbonate</arm_group_label>
    <other_name>fluimukan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  angina (stable, unstable)

          -  coronary artery disease

          -  cardiomyopathy

          -  valvular disease

          -  vasculitis

          -  peripheral arterial disease

        Exclusion Criteria:

          -  kidney dysfunction

          -  uncontrolled hypertension (systolic blood pressure &gt;160 mm Hg and/or diastolic blood
             pressure &gt;100 mm Hg)

          -  pregnancy

          -  lactation

          -  history of allergic reaction to contrast agents

          -  cardiogenic shock

          -  pulmonary edema

          -  multiple myeloma

          -  urgent coronary angiography

          -  receiving contrast agents two days prior to the study and 48 hours within the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2016</study_first_posted>
  <last_update_submitted>May 2, 2016</last_update_submitted>
  <last_update_submitted_qc>May 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Clinical Hospital Centre Zagreb</investigator_affiliation>
    <investigator_full_name>Ana Vujaklija Brajkovic</investigator_full_name>
    <investigator_title>M.D. PhD</investigator_title>
  </responsible_party>
  <keyword>Acetylcysteine</keyword>
  <keyword>Sodium Bicarbonate</keyword>
  <keyword>Lipocalins</keyword>
  <keyword>Creatinine</keyword>
  <keyword>Blood Urea Nitrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

